循環器ジャーナル68巻1号

2020年01月発行

特集 U40世代が描く心不全診療の現状と未来—基礎研究を識り，臨床を素心深考する Ⅰ．心筋症

—臨床編—がん治療関連心機能障害の予後予測因子はありますか？

著者： 石田純一¹

所属機関： ¹東京大学大学院医学系研究科循環器内科学

ページ範囲：P.56 - P.61

Point
・がん治療関連心機能障害は「左室駆出率の10%以上かつ正常下限値未満への低下」と定義される．
・代表的な原因薬剤は，アントラサイクリンとトラスツズマブである．
・発症機序に関して不明な部分が多いため，特異的な治療がない．
・治療は心不全診療ガイドラインに沿った心保護治療が中心である．

参考文献

1) Plana JC, Galderisi M, Barac A, et al:Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy:a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911-939, 2014

2) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guideline. Eur Heart J 37:2768-2801, 2016

3) Cardinale D, Colombo A, Bacchiani G, et al:Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988, 2015

4) Ichikawa Y, Ghanefar M, Bayeva M, et al:Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124:617-630, 2014

5) van Dalen EC, Caron HN, Dickinson HO, et al:Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 6:CD003917, 2011

6) Vejpongsa P, Yeh E:Topoisomerase 2β:a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95:45-52, 2014

7) Henriksen PA:Anthracycline cardiotoxicity:an update on mechanisms, monitoring and prevention. Heart 104:971-977, 2018

8) Cardinale D, Colombo A, Sandri MT, et al:Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. Circulation 114:2474-2481, 2006

9) Sawaya H, Sebag IA, Plana JC, et al:Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5:596-603, 2012

10) Marwick T, Negishi T:Strain surveillance during chemotherapy for improving cardiovascular outcomes（SUCCOUR Study）.

11) Cardinale D, Sandri MT, Colombo A, et al:Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754, 2004

12) Slamon DJ, Leyland-Jones B, Shak S, et al:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001

13) Negro A, Brar BK, Lee KF:Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1-12, 2004

14) Goel S, Liu J, Guo H, et al:Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail 7:795-804, 2019

15) Gulati G, Heck SL, Ree AH, et al:Prevention of cardiac dysfunction during adjuvant breast cancer therapy（PRADA）:a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671-1680, 2016

16) Pituskin E, Mackey JR, Koshman S, et al:Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research（MANTICORE 101-Breast）:A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 35:870-877, 2017

17) Johnson DB, Balko JM, Compton ML, et al:Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375:1749-1755, 2016